Revolade 75mg

1
ELTROMBOPAG 75MGMHP

• REVOLADE 75 MG

2
DESCRIPTION

• Eltrombopag is sold under the brand name Revolade
  and it is a man-made form of a protein that
  increases production of platelets (blood-clotting
  cells) in your body. Revolade 75mg can reduces
  the risk of bleeding by increasing platelets in
  your blood.Revolade 75mg tablet which is used
  asprescription drug under the guidance of the
  medical practioners

3
INDICATION
4
INDICATION

• Revolade 75mg is an anticancer medication which
  isIndicated for the treatment of patients
  having Severe aplastic Anemia First line
  treatment of severe aplastic Anemia Treatment
  of refractory severe aplastic AnemiaIndicated
  for the treatment to stimulate the growth and
  development of platelets in the bone
  marrowPrimarily indicated for the treatment of
  patients having reduced platelet counts due to
  chronic hepatitis C virus infection

5
INDICATION
6
MECHANISM OF ACTION
7
MECHANISM OF ACTION

• Eltrombopag consist of class of drugs known as
  thrombopoietin (TPO) receptor agonists. A class
  of drugs is a group of medications which work in
  a same way.Eltrombopag mechanism by raising
  cells in your bone marrow and causes these cells
  to make more platelets. This effect reduces your
  risk of bleeding.

8
PROPERTIES
9
PROPERTIES

• Ingredients  Eltrombopag 
• Strength  75mg
• Package  7 tablets in a strip

10
ADD ME

• AbsorptionHigh plasma concentration is 2-6
  hours
• DistributionMaximum human plasma protein
  bounding is gt99 and in blood plasma level is 50
  to 79
• Metabolism
• generally metabolised via cleavage,
  oxidation and
• conjugation with glucuronic acid.

11
ADD ME

• EliminationRevolade 75mg eliminated mainly via
  feces 59, along with 31 via renally excreted
• Revolade 75mg Half-life for healthy patients is
  21-23 hours and idiopathic thrombocytopenic
  purpura is 26-35 hours.

12
DOSAGE MANAGEMENT

• The usual dose for Chronic Hepatitis C-associated
  Thrombocytopenia is 25 mg PO qDay. Dose is
  managed in 25 mg accretion q2weeks PRN to attain
  target Plt needed to start/control antiviral
  therapy with pegylated interferon and ribavirin
  not to exceed 100 mg/day. 

13
Severe Aplastic Anemia

• First-line therapy When combination with
  standard immunosuppressive treatment, for
  patients with serious aplastic Anemia (SAA) The
  usual dose for severe Aplastic Anemia 150 mg PO
  qDay for 6 months Avoid taking of more than
  starting dose total duration is 6 months 

14
Severe Aplastic Anemia

• Refractory SAA In this condition the drug given
  who fail to respond enough to at least 1 before
  immunosuppressive therapy The usual dose for
  Refractory SAA 50 mg PO qDay 

15
Severe Aplastic Anemia

• The recommended dose for Chronic Immune
  Thrombocytopenia is 50 mg PO qDay Adjust dose to
  manage and control platelet count (Plt) gt50 x
  109/L to reduce the risk of bleeding not to
  exceed 75 mg/day

16
PRECAUTIONS

• The drug Revolade 75mg may have high risk of
  severe and probably life-threatening
  hepatotoxicity monitor liver function before and
  during treatment
• While receiving the drug, if patient with hepatic
  impairment (Child-Pugh Class A, B, C) initiates
  therapy for first- line treatment of severe
  aplastic Anemia, reduce initial dose

17
(No Transcript)
18
PRECAUTIONS

• When treatment, If the patients have cataracts,
  do not use the drug due to the Revolade
  75mg effects cataracts and make the condition
  worse.
• Avoid the Revolade 75mg while the patients have
  myelodysplastic syndrome (MDS), will increases
  the risk of death.
• While on treatment with drug Revolade then
  Portal vein thrombosis reported in patients with
  chronic liver disease.

19
SIDE EFFECTS

• Common side effects of Revolade 75mg 
  Headache Cough Loss of appetite Flu
  Reduced red blood cells Diarrhoea Nausea
  Fever Weakness

20
SIDE EFFETCS

• Serious side effects of Revolade 75mg 
  Swelling of legs Abdomen swelling Confusion
  Chest pain Dyspnea Cloudy vision Urine in
  dark colour Yellowing of your skin
  Sensitivity to light Seeing circles around
  lights

21
DRUG INTERACTION

• PREGNANCY
• Pregnancy category is C Safety of drug
  during pregnancy is not established
• LACTATION
• During breast feeding, avoid using of
  drug Revolade
• 75mg
• STORAGE
• Store at room temperature 20C and 25C.

22
CONTACT US

• PHONE NO
• 91-9940472902
• EMAIL
• millionhealthpharmaceuticals_at_gmail.com
   
• WEBSITE
• https//millionpharma.com/eltrombopag-
  
• 75mg.php

23
(No Transcript)